次世代乳がん診断・スクリーニング市場：製品、診断技術、スクリーニング技術、用途、エンドユーザー別-2025-2030年の世界予測

次世代乳がん診断・スクリーニング市場は、2023年に228億1,000万米ドルと評価され、2024年には251億2,000万米ドルに達すると予測され、CAGR 10.91％で成長し、2030年には471億1,000万米ドルに達すると予測されています。

次世代乳がん診断・スクリーニング市場には、ゲノミクス、プロテオミクス、リキッドバイオプシーなど、乳がんの早期発見、診断、モニタリングの改善を目的とした先進技術や手法が含まれます。こうした技術革新の必要性は、乳がん罹患率の増加、非侵襲的手法の需要、個別化ケアの必要性から生じています。がんリスク評価のための遺伝子検査、AIを活用した画像診断システムによる早期発見、治療効果のリアルタイムモニタリングなど、その応用範囲は広いです。エンドユーザーは主に病院、診断研究所、研究機関、個別化医療企業などです。市場の洞察によると、ヘルスケアに対する意識の高まり、技術の進歩、政府支援の増加、価値に基づくケアへのシフトが成長の原動力となっています。AIと機械学習の統合の拡大、予測分析の提供、十分なサービスを受けていない人々にアプローチするためのポータブルで費用対効果の高い診断ツールの開発にはビジネスチャンスがあります。企業にとって、ハイテク企業との提携や研究開発への投資は、こうした機会を生かすことができます。しかし、高コスト、厳しい規制の枠組み、低所得地域でのアクセスの制限など、ある種の制約が成長を妨げています。また、データ・プライバシーに関する懸念や、高度なスキルを持つ専門家の必要性といった課題もあります。マルチオミクスデータのシームレスな統合、手ごろな価格の診断キットの開発、リアルタイムのAI分析などの分野における革新は、成長の有望な道筋を示すものです。さらに、在宅診断ソリューションなど、患者中心のケアイノベーションに注力することで、競争力を高めることができます。市場は急速な技術導入と高い競合を特徴とするダイナミックな市場であるため、継続的なイノベーションが促進され、強固な適応戦略が必要となります。成功の鍵は、多くの場合、共同研究、戦略的パートナーシップ、規制変更への対応にあります。企業に対する戦略的な提言としては、乳がんを理解し闘うための全体的なアプローチを促進するために、顧客教育とエンゲージメントへの投資、透明性による信頼の確立、学際的なコラボレーションの優先などが挙げられます。

市場力学：急速に進化する次世代乳がん診断・スクリーニング市場の主要市場インサイトを公開

次世代乳がん診断・スクリーニング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の乳がん罹患率の上昇
  • 疾患の早期診断と治療への志向の高まり
  • 乳がんに関する認識を高めるための政府の取り組み
• 市場抑制要因
  • 高価な乳がん診断・スクリーニング技術
• 市場機会
  • 次世代乳がん診断・スクリーニング技術の進歩
  • 革新的な乳がん診断ソリューションを製造するための戦略的提携と投資
• 市場の課題
  • 製造の複雑さと規制当局の厳しい承認プロセス

ポーターのファイブフォース：次世代乳がん診断・スクリーニング市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：次世代乳がん診断・スクリーニング市場における外部からの影響の把握

外部マクロ環境要因は、次世代乳がん診断・スクリーニング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析次世代乳がん診断・スクリーニング市場における競合情勢の把握

次世代乳がん診断・スクリーニング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス次世代乳がん診断・スクリーニング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、次世代乳がん診断・スクリーニング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨次世代乳がん診断・スクリーニング市場における成功への道筋を描く

次世代乳がん診断・スクリーニング市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で乳がん罹患率が上昇
    • 病気の早期診断と治療への傾向の高まり
    • 乳がんに関する意識を高める政府の取り組み
  • 抑制要因
    • 高価な乳がん診断・スクリーニング技術
  • 機会
    • 次世代乳がん診断・スクリーニングテクノロジーの進歩
    • 革新的な乳がん診断ソリューションを製造するための戦略的提携と投資
  • 課題
    • 製造の複雑さと厳格な規制承認プロセス
• 市場セグメンテーション分析
  • 製品：臨床結果の向上のための高度な乳房画像システムの必要性
  • エンドユーザー：より幅広い患者層に対応するために、病院での乳がん診断の利用を拡大する
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 次世代乳がん診断・スクリーニング市場：製品別

• アクセサリー
• 乳房画像診断システム
• ソフトウェアとサービス

第7章 次世代乳がん診断・スクリーニング市場診断技術

• DNAマイクロアレイ
• ラボオンチップと逆転写PCR
• 分子診断
• 次世代シーケンシング
• タンパク質マイクロアレイ
• qPCRとマルチプレックス

第8章 次世代乳がん診断・スクリーニング市場スクリーニングテクノロジー

• イオン化乳房画像技術
  • 3D乳房トモシンセシス
  • アナログマンモグラフィー
  • コーンビームコンピュータ断層撮影（CBCT）
  • 造影マンモグラフィー（CEM）
  • フルフィールドデジタルマンモグラフィー（FFDM）
  • 分子乳房イメージング/乳房特異的ガンマイメージング（MBI/BSGI）
  • 陽電子放出マンモグラフィー（PEM）
  • 陽電子放出断層撮影およびコンピュータ断層撮影（PET-CT）
• 非電離乳房画像診断技術
  • 自動全乳房超音波検査（AWBU）
  • 乳房MRI
  • 乳房サーモグラフィー
  • 乳房超音波検査
  • 電気インピーダンストモグラフィー
  • 光学イメージング

第9章 次世代乳がん診断・スクリーニング市場：用途別

• がん検診
• コンパニオン診断
• リスク分析
• 治療モニタリング

第10章 次世代乳がん診断・スクリーニング市場：エンドユーザー別

• 乳がんケアセンター
• 画像診断センター
• 病院・クリニック

第11章 南北アメリカの次世代乳がん診断・スクリーニング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の次世代乳がん診断・スクリーニング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの次世代乳がん診断・スクリーニング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • GEヘルスケア、乳がん検出の迅速化で臨床医をサポートするMyBreastAIスイートをリリース
  • Exact Sciencesは先見性のあるコラボレーションを通じて革新的ながん技術とアプローチを推進します
  • サーモフィッシャーサイエンティフィックとファイザーが提携し、国際市場でがん患者向けの次世代シーケンシングベースの検査への地域的アクセスを拡大
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Agendia Inc.
• Agilent Technologies, Inc.
• ARTIVION INC.
• Becton, Dickinson and Company
• Benitec Biopharma Ltd
• BGI Genomics Co., Ltd.
• Bio-Rad Laboratories, Inc.
• Centogene N.V.
• Danaher Corporation
• Epic Sciences, Inc.
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Fujifilm Holdings Corporation
• GE HealthCare Technologies, Inc.
• Hologic, Inc.
• Illumina, Inc.
• Invivoscribe, Inc.
• Koninklijke Philips N.V.
• Laboratory Corporation of America Holdings
• Merck & Co., Inc.
• Myriad Genetics, Inc.
• Novartis AG
• Pfizer Inc.
• QIAGEN N.V.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET RESEARCH PROCESS
• FIGURE 2. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET DYNAMICS
• TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY 3D BREAST TOMOSYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CONE-BEAM COMPUTED TOMOGRAPHY (CBCT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CONTRAST-ENHANCED MAMMOGRAPHY (CEM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING/BREAST SPECIFIC GAMMA IMAGING (MBI/BSGI), BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY POSITRON EMISSION MAMMOGRAPHY (PEM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET-CT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY AUTOMATED WHOLE-BREAST ULTRASOUND (AWBU), BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST MRI, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ELECTRIC IMPEDANCE TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 72. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 73. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 109. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 110. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 112. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 113. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 114. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 116. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 117. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 130. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 133. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 141. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 148. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 154. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 158. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 161. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 162. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 163. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 165. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 166. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 168. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 169. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 170. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 172. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 173. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 176. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 177. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 179. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 180. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 190. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 191. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 193. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 194. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 195. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 197. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 198. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 199. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 201. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 202. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 207. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 208. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 209. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 211. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 212. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 213. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 214. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 215. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 216. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 218. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 219. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 220. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 222. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 223. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 226. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 227. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 229. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 230. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 232. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 233. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 234. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 235. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 236. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 237. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 238. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 240. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 241. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 20

The Next-Generation Breast Cancer Diagnostic & Screening Market was valued at USD 22.81 billion in 2023, expected to reach USD 25.12 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 47.11 billion by 2030.

The scope of the next-generation breast cancer diagnostic and screening market encompasses advanced technologies and methodologies aimed at improving early detection, diagnosis, and monitoring of breast cancer, like genomics, proteomics, and liquid biopsy. Necessity for these innovations stems from increasing breast cancer incidence, demand for non-invasive methods, and the need for personalized care. Applications are broad, including genetic tests for assessing cancer risk, early-stage detection using AI-enhanced imaging systems, and real-time monitoring of treatment efficacy. End-users primarily include hospitals, diagnostic laboratories, research institutes, and personalized medicine companies. Market insights reveal growth driven by rising healthcare awareness, technological advancements, increased governmental support, and a shift towards value-based care. Opportunities are evident in expanding AI and machine learning integrations, offering predictive analytics, and developing portable, cost-effective diagnostic tools to reach underserved populations. For businesses, partnership with tech firms and investing in R&D can capitalize on these opportunities. However, certain limitations impede growth, including high costs, stringent regulatory frameworks, and limited access in low-income regions. Challenges also include data privacy concerns and the need for highly skilled professionals. Innovating in areas such as seamless integration of multi-omics data, developing affordable diagnostic kits, and real-time AI analytics represents promising avenues for growth. Moreover, focus on patient-centered care innovations, such as home-based diagnostic solutions, can provide a competitive edge. The market is dynamic, characterized by rapid technology adoption and high competition, which fosters continuous innovation and necessitates robust adaptive strategies. Success often hinges on collaborations, strategic partnerships, and aligning with regulatory changes. Strategic recommendations for businesses involve investing in customer education and engagement, establishing trust through transparency, and prioritizing cross-disciplinary collaborations to foster a holistic approach to understanding and combating breast cancer.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Breast Cancer Diagnostic & Screening Market

The Next-Generation Breast Cancer Diagnostic & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of breast cancer worldwide
  • Growing inclination towards early diagnosis and treatment of diseases
  • Government initiatives to raise awareness regarding breast cancer
• Market Restraints
  • Expensive breast cancer diagnostic & screening technologies
• Market Opportunities
  • Advancements in next-generation breast cancer diagnostic & screening technologies
  • Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
• Market Challenges
  • Complexity in manufacturing and stringent regulatory approval process

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Breast Cancer Diagnostic & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Breast Cancer Diagnostic & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Breast Cancer Diagnostic & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Breast Cancer Diagnostic & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Breast Cancer Diagnostic & Screening Market

A detailed market share analysis in the Next-Generation Breast Cancer Diagnostic & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Breast Cancer Diagnostic & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Breast Cancer Diagnostic & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Breast Cancer Diagnostic & Screening Market

A strategic analysis of the Next-Generation Breast Cancer Diagnostic & Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Accessories, Breast Imaging Systems, and Software & Services.
• Based on Diagnostic Technology, market is studied across DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
• Based on Screening Technology, market is studied across Ionizing Breast Imaging Technologies and Non-ionizing Breast Imaging Technologies. The Ionizing Breast Imaging Technologies is further studied across 3D Breast Tomosynthesis, Analog Mammography, Cone-Beam Computed Tomography (CBCT), Contrast-Enhanced Mammography (CEM), Full-Field Digital Mammography (FFDM), Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI), Positron Emission Mammography (PEM), and Positron Emission Tomography and Computed Tomography (PET-CT). The Non-ionizing Breast Imaging Technologies is further studied across Automated Whole-Breast Ultrasound (AWBU), Breast MRI, Breast Thermography, Breast Ultrasound, Electric Impedance Tomography, and Optical Imaging.
• Based on Application, market is studied across Cancer Screening, Companion Diagnostics, Risk Analysis, and Therapeutic Monitoring.
• Based on End User, market is studied across Breast Care Centers, Diagnostic Imaging Centers, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of breast cancer worldwide
    • 5.1.1.2. Growing inclination towards early diagnosis and treatment of diseases
    • 5.1.1.3. Government initiatives to raise awareness regarding breast cancer
  • 5.1.2. Restraints
    • 5.1.2.1. Expensive breast cancer diagnostic & screening technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in next-generation breast cancer diagnostic & screening technologies
    • 5.1.3.2. Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in manufacturing and stringent regulatory approval process
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Need for advanced breast imaging systems for enhanced clinical outcomes
  • 5.2.2. End User: Expanding use of breast cancer diagnostics in hospitals to cater to a wider patient population
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Next-Generation Breast Cancer Diagnostic & Screening Market, by Product

• 6.1. Introduction
• 6.2. Accessories
• 6.3. Breast Imaging Systems
• 6.4. Software & Services

7. Next-Generation Breast Cancer Diagnostic & Screening Market, by Diagnostic Technology

• 7.1. Introduction
• 7.2. DNA Microarrays
• 7.3. Lab-on-a-Chip & Reverse Transcriptase-PCR
• 7.4. Molecular Diagnostics
• 7.5. Next Generation Sequencing
• 7.6. Protein Microarrays
• 7.7. qPCR & Multiplexing

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Screening Technology

• 8.1. Introduction
• 8.2. Ionizing Breast Imaging Technologies
  • 8.2.1. 3D Breast Tomosynthesis
  • 8.2.2. Analog Mammography
  • 8.2.3. Cone-Beam Computed Tomography (CBCT)
  • 8.2.4. Contrast-Enhanced Mammography (CEM)
  • 8.2.5. Full-Field Digital Mammography (FFDM)
  • 8.2.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
  • 8.2.7. Positron Emission Mammography (PEM)
  • 8.2.8. Positron Emission Tomography and Computed Tomography (PET-CT)
• 8.3. Non-ionizing Breast Imaging Technologies
  • 8.3.1. Automated Whole-Breast Ultrasound (AWBU)
  • 8.3.2. Breast MRI
  • 8.3.3. Breast Thermography
  • 8.3.4. Breast Ultrasound
  • 8.3.5. Electric Impedance Tomography
  • 8.3.6. Optical Imaging

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

• 9.1. Introduction
• 9.2. Cancer Screening
• 9.3. Companion Diagnostics
• 9.4. Risk Analysis
• 9.5. Therapeutic Monitoring

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

• 10.1. Introduction
• 10.2. Breast Care Centers
• 10.3. Diagnostic Imaging Centers
• 10.4. Hospitals & Clinics

11. Americas Next-Generation Breast Cancer Diagnostic & Screening Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
  • 14.3.2. Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
  • 14.3.3. Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agendia Inc.
• 3. Agilent Technologies, Inc.
• 4. ARTIVION INC.
• 5. Becton, Dickinson and Company
• 6. Benitec Biopharma Ltd
• 7. BGI Genomics Co., Ltd.
• 8. Bio-Rad Laboratories, Inc.
• 9. Centogene N.V.
• 10. Danaher Corporation
• 11. Epic Sciences, Inc.
• 12. Exact Sciences Corporation
• 13. F. Hoffmann-La Roche Ltd.
• 14. Fujifilm Holdings Corporation
• 15. GE HealthCare Technologies, Inc.
• 16. Hologic, Inc.
• 17. Illumina, Inc.
• 18. Invivoscribe, Inc.
• 19. Koninklijke Philips N.V.
• 20. Laboratory Corporation of America Holdings
• 21. Merck & Co., Inc.
• 22. Myriad Genetics, Inc.
• 23. Novartis AG
• 24. Pfizer Inc.
• 25. QIAGEN N.V.
• 26. Siemens Healthineers AG
• 27. Thermo Fisher Scientific Inc.